

# Samantha Hinsley

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/910911/publications.pdf>

Version: 2024-02-01

19  
papers

1,011  
citations

1163117

8  
h-index

794594

19  
g-index

19  
all docs

19  
docs citations

19  
times ranked

1702  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Road Map for Designing Phase I Clinical Trials of Radiotherapyâ€“Novel Agent Combinations. <i>Clinical Cancer Research</i> , 2022, 28, 3639-3651.	7.0	2
2	MUK<i>nine</i> OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia. <i>BMJ Open</i> , 2021, 11, e046225.	1.9	18
3	Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUK<i>five</i>). <i>Haematologica</i> , 2021, 106, 2694-2706.	3.5	6
4	Identification of a Locus Near <i>ULK1</i> Associated With Progression-Free Survival in Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1669-1680.	2.5	5
5	Serum Proteomics and Plasma Fibulin-3 in Differentiation of Mesothelioma From Asbestos-Exposed Controls and Patients With Other Pleural Diseases. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1705-1717.	1.1	10
6	CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer. <i>Clinical and Translational Radiation Oncology</i> , 2020, 25, 61-66.	1.7	15
7	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). <i>Clinical Cancer Research</i> , 2020, 26, 5411-5423.	7.0	43
8	Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial. <i>Journal of the National Cancer Institute</i> , 2018, 110, 871-879.	6.3	32
9	Maintenance with Carfilzomib Following Carfilzomib, Cyclophosphamide and Dexamethasone at First Relapse or Primary Refractory Multiple Myeloma (MM) on the Phase 2 Muk Five Study: Effect on Minimal Residual Disease. <i>Blood</i> , 2018, 132, 802-802.	1.4	6
10	Carfilzomib Versus Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): Outcomes Based on Genetic Risk and Long Term Follow up of the Phase 2 Muk Five Study. <i>Blood</i> , 2018, 132, 306-306.	1.4	3
11	Reproductive hormone analyses and effects of adjuvant zoledronic acid in early breast cancer â€“ An AZURE (BIG 01/04) sub-study. <i>Journal of Bone Oncology</i> , 2017, 9, 48-54.	2.4	5
12	Carfilzomib, Cyclophosphamide and Dexamethasone (KCD) Versus Bortezomib, Cyclophosphamide and Dexamethasone (VCD) for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): First Final Analysis of the Phase 2 Muk Five Study. <i>Blood</i> , 2017, 130, 835-835.	1.4	6
13	The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma. <i>BMC Hematology</i> , 2016, 16, 14.	2.6	7
14	Lung stereotactic ablative radiotherapy (SABR): dosimetric considerations for chest wall toxicity. <i>British Journal of Radiology</i> , 2016, 89, 20150628.	2.2	15
15	Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. <i>Lancet</i> , The, 2015, 386, 1353-1361.	13.7	581
16	Carfilzomib, Cyclophosphamide and Dexamethasone Is Well Tolerated in Patients with Relapsed/Refractory Multiple Myeloma Who Have Received One Prior Regimen. <i>Blood</i> , 2015, 126, 1840-1840.	1.4	5
17	Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG) Tj ETQq1 1 0.784314 rgBT /Over 10.7 247	10.7	247
18	Lenalidomide Combined With Cyclophosphamide and Dexamethasone Is Effective and Well Tolerated Induction Treatment For Newly Diagnosed Myeloma Patients Of All Ages. <i>Blood</i> , 2013, 122, 540-540.	1.4	3

#	ARTICLE	IF	CITATIONS
19	Newly Diagnosed Multiple Myeloma (MM) Patients Treated With Lenalidomide Induction and Maintenance Show a Low Incidence Of Second Primary Malignancies (SPMs). Blood, 2013, 122, 2074-2074.	1.4	2